1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2 |
Wu C, Li M, Meng H, et al. Analysis of status and countermeasures of cancer incidence and mortality in China[J]. Sci China Life Sci, 2019, 62(5): 640-647.
|
3 |
Villalobos P, Wistuba II. Lung cancer biomarkers[J]. Hematol Oncol Clin North Am, 2017, 31(1): 13-29.
|
4 |
Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung cancer[J]. Expert Opin Investig Drugs, 2014, 23(5): 675-692.
|
5 |
Porporato PE, Filigheddu N, Pedro JMB, et al. Mitochondrial metabolism and cancer[J]. Cell Res, 2018, 28(3): 265-280.
|
6 |
Kim HJ, Maiti P, Barrientos A. Mitochondrial ribosomes in cancer[J]. Semin Cancer Biol, 2017, 47: 67-81.
|
7 |
Senft D, Ronai ZA. Regulators of mitochondrial dynamics in cancer[J]. Curr Opin Cell Biol, 2016, 39: 43-52.
|
8 |
Marty L, Taviaux S, Fort P. Expression and human chromosomal localization to 17q25 of the growth-regulated gene encoding the mitochondrial ribosomal protein MRPL12[J]. Genomics, 1997, 41(3): 453-457.
|
9 |
Wang ZB, Cotney J, Shadel GS. Human mitochondrial ribosomal protein MRPL12 interacts directly with mitochondrial RNA polymerase to modulate mitochondrial gene expression[J]. J Biol Chem, 2007, 282(17): 12610-12618.
|
10 |
Serre V, Rozanska A, Beinat M, et al. Mutations in mitochondrial ribosomal protein MRPL12 leads to growth retardation, neurological deterioration and mitochondrial translation deficiency[J]. Biochim Biophys Acta, 2013, 1832(8): 1304-1312.
|
11 |
Sy SM, Wong N, Mok TS, et al. Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity[J]. Lung Cancer, 2003, 41(1): 91-99.
|
12 |
Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(w1): W509-W514.
|
13 |
Tang ZF, Li CW, Kang BX, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses[J]. Nucleic Acids Res, 2017, 45(W1): W98-W102.
|
14 |
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649-658.
|
15 |
Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types[J]. Nucleic Acids Res, 2018, 46(d1): D956-D963.
|
16 |
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2009, 4(1): 44-57.
|
17 |
Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol, 2011, 12(2): 175-180.
|
18 |
Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments[J]. Arch Pathol Lab Med, 2013, 137(9): 1191-1198.
|
19 |
邓垒, 张文珏, 周宗玫, 等. 327例广泛期小细胞肺癌综合治疗的疗效分析[J]. 国际放射医学核医学杂志, 2018, 42(1): 1-8.
|
20 |
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
|
21 |
Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072): 917-929.
|
22 |
Surovtseva YV, Shutt TE, Cotney J, et al. Mitochondrial ribosomal protein L12 selectively associates with human mitochondrial RNA polymerase to activate transcription[J]. PNAS, 2011, 108(44): 17921-17926.
|
23 |
Amunts A, Brown A, Toots J, et al. Ribosome. The structure of the human mitochondrial ribosome[J]. Science, 2015, 348(6230): 95-98.
|
24 |
Lamb R, Ozsvari B, Lisanti CL, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease[J]. Oncotarget, 2015, 6(7): 4569-4584.
|
25 |
Marty L, Fort P. A delayed-early response nuclear gene encoding MRPL12, the mitochondrial homologue to the bacterial translational regulator L7/L12 protein[J]. J Biol Chem, 1996, 271(19): 11468-11476.
|
26 |
Nouws J, Goswami AV, Bestwick M, et al. Mitochondrial ribosomal protein L12 is required for POLRMT stability and exists as two forms generated by alternative proteolysis during import[J]. J Biol Chem, 2016, 291(2): 989-997.
|
27 |
Zhang QL, Liang Z, Gao YX, et al. Differentially expressed mitochondrial genes in breast cancer cells: potential new targets for anti-cancer therapies[J]. Gene, 2017, 596: 45-52.
|
28 |
Vatapalli R, Sagar V, Rodriguez Y, et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer[J]. Nat Commun, 2020, 11(1): 4153.
|
29 |
Ge Z, Guo X, Li JY, et al. Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia[J]. Oncotarget, 2015, 6(39): 42300-42311.
|
30 |
Müller J, Eilers M. Ubiquitination of Myc: proteasomal degradation and beyond[J]. Ernst Schering Found Symp Proc, 2008(1): 99-113.
|